AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01412983 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ciba Vision soft contact lens
Description: Lens to be worn on a daily wear basis for one week. Participants will be provided with Bausch + Lomb renu® fresh™ multi-purpose solution for daily rinsing, cleaning, and disinfecting of their lenses.
Study NCT02569242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT02569242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel/Paclitaxel
Study NCT03088462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial treatment
Description: Any psychosocial treatment participant is involved in such as individual therapy, group therapy, or support groups.
Study NCT03088462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LiveWell Program
Description: Participants work with a health coach to facilitate use of a smartphone application designed for people with bipolar disorder.
Study NCT03663738 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mobile app NOVAME
Description: The training program is divided into 3 periods of 21 days, where each day the patient receives a new formation pill. At the end of one of these periods there will be a week of review in which the patient will receive reminders of the contents that he has already received. These pills will help the patient to acquire healthy lifestyle habits and improve the control of the disease. The length of the program is 84 days, and once completed, the patient can repeat or intensify efforts in the areas he considers and continue to have access to the virtual coach. Patients assigned to the intervention group will receive a brief structured explanation on how to use the application and its contents.
Study NCT04814901 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Curing small and medium sized oronasal fistula
Description: * Flap will be marked medial to the duct, which limits posterior extent of flap. Anterior flap marking starts 1cm posterior to oral commissure.~* Width of flap was kept to about 2-2.5cm.~* An initial incision will be made 1cm posterior to oral commissure.~* Incision will be deepened through buccal mucosa, submucosa, \& underlying muscles into layer of buccal fat.~* Flap will be dissected in a retrograde or antegrade manner depending on fistula site, maintaining vessels in a central position in the flap.~* Once completely raised, flap inserted \& sutured in place while donor site be closed primarily with 4-0 polyglactin (Vicryl) interrupted sutures.~* Patient's comparator group will be treated by raising a palatal pedicled flap.~* Flap will be outlined extending from palatal mucosa against permanent 2nd molar till permanent canine anteriorly.~* It is rotated towards oronasal fistula \& secured in place using 4 -0 Vicryl interrupted sutures.
Study NCT04814901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Curing small and medium sized oronasal fistula
Description: * Flap will be marked medial to the duct, which limits posterior extent of flap. Anterior flap marking starts 1cm posterior to oral commissure.~* Width of flap was kept to about 2-2.5cm.~* An initial incision will be made 1cm posterior to oral commissure.~* Incision will be deepened through buccal mucosa, submucosa, \& underlying muscles into layer of buccal fat.~* Flap will be dissected in a retrograde or antegrade manner depending on fistula site, maintaining vessels in a central position in the flap.~* Once completely raised, flap inserted \& sutured in place while donor site be closed primarily with 4-0 polyglactin (Vicryl) interrupted sutures.~* Patient's comparator group will be treated by raising a palatal pedicled flap.~* Flap will be outlined extending from palatal mucosa against permanent 2nd molar till permanent canine anteriorly.~* It is rotated towards oronasal fistula \& secured in place using 4 -0 Vicryl interrupted sutures.
Study NCT00710437 — intervention group
Intervention type: DRUG
Intervention: Dexmedetomidine
Description: Steady state infusion 0.007 mcg/kg/min
Study NCT01270867 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Thrombectomy
Description: Each arm will use either Merci or Trevo as the primary Mechanical Thrombectomy device.
Study NCT01270867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Thrombectomy
Description: Each arm will use either Merci or Trevo as the primary Mechanical Thrombectomy device.
Study NCT01117350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: 100 Units/mL solution for injection in a pre-filled SoloStar pen
Study NCT02035423 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 120 IU milk
Description: Daily consumption of milk fortified with 120 IU vitamin D
Study NCT01117350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: 6 mg/mL solution for injection in a 3-mL pre-filled pen (18mg)
Study NCT01117350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin was a background treatment, mandatory for each patient randomized in the study (at the minimum dose of 1g/day). It was not supplied by the sponsor.
Study NCT01117350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin was a background treatment, mandatory for each patient randomized in the study (at the minimum dose of 1g/day). It was not supplied by the sponsor.
Study NCT03806257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Physical Therapy Protocol
Description: A structured physical therapy protocol that requires subject to ambulate more frequently than the standard-of-care patient.
Study NCT03958487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video feedback, Feedback online
Description: The treatment phase have 3 timepoints, 1 the patient is asked to perform an ADL alone, 2. Video feedback is administrated. This requires the participant to watch its own videotaped performance with the therapist while the therapist encourage the participant to identify errors, areas of strength, and to suggest strategies to solve errors in future sessions. 3. feedback online will be provided by the therapist on participant performance. The therapist will wait for the patient to detect and correct their error spontaneously. If the patient does not detect it, the therapist provides unspecified/specific help. This strategy is based on previous work (Schmidt, et al 2013, Ownstorth et al. 2010). The novelty of our procedure is the inclusion of distracting and conflicting/problem solving situations to be inhibited, detected and solved. Feedback will focus on these situations. The level of monitoring requirements will be adjusted to participants performance using a changing criterion design.
Study NCT04134312 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Brachyury
Description: MVA-BN-Brachyury will be administered intravenously every three weeks with three administrations in total at the dose indicated by the enrolled cohort.
Study NCT01219075 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy isoflavones
Description: Given orally
Study NCT01219075 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT01219075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01219075 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01219075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Correlative studies
Study NCT01219075 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: magnetic resonance imaging
Description: Correlative studies
Study NCT01219075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies
Study NCT01219075 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: biopsy
Description: Correlative studies
Study NCT01219075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT01219075 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT01219075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02035423 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 200 IU Milk
Description: Daily Consumption of milk fortified with 200 IU vitamin D
Study NCT02035423 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Non-Fortified Milk
Description: Daily consumption of non-fortified milk
Study NCT04133324 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: C-reactive protein
Description: C-reactive protein at postoperative days four and two.
Study NCT03170284 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab is prescribed by physicians as per SPC.
Study NCT01236885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computer-assisted intervention
Description: Undergo blood glucose management using Glucommander
Study NCT03937986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: The pharmacodynamic effects of suvorexant maintenance will be determined.
Study NCT03937986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and suvorexant.
Study NCT03937986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and suvorexant.
Study NCT03937986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: The pharmacodynamic effects of placebo will be determined.
Study NCT03668548 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine
Description: 192 mg/kg body mass/day
Study NCT03668548 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A taste and calorie-matched placebo
Study NCT02348567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unannounced hospital surveys
Description: This is a cluster-randomised controlled trial performed at hospital level. We hypothesise that unannounced surveys produce less successful assessments of patient safety compared to announced surveys (conventional/control). This study defines less successful as less compliance with the included standards and performance indicators.
Study NCT02348567 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: announced hospital surveys
Study NCT03172650 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: glomerular filtration rate
Description: collection of blood sample 5 milliliter for calculation of glomerular filtration rate
Study NCT03219125 — intervention group
Intervention type: DEVICE
Intervention: Dixon Magnetic Resonance Imaging
Description: MRI of the lumbar spine (L1 to L4) and hip (non-dominant) for the measurement of Ad Med. (In%) by the DIXON sequence.
Study NCT03219125 — intervention group
Intervention type: DEVICE
Intervention: dual-energy X-ray absorptiometry (DXA)
Description: Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.
Study NCT03244371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood draw
Description: 4 blood draws of 25 mls of blood will be performed at 4 differents time points (before treatment, 4 weeks later, at the end of the treatment and 6 months after the end of the treatment)
Study NCT00844246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Developmental screening using ASQ and MCHAT
Description: In the SRS intervention arm subjects will complete developmental screening tools with a school readiness specialist at their 9, 18, 24 and 30 month well child visits and then complete their well child visit with their primary care clinician to discuss the results.
Study NCT00844246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Developmental screening using ASQ and MCHAT
Description: Subjects who are randomized to PCP arm will be screened for developmental delays by their Primary Care Clinician at their 9, 18, 24 and 30 month well child visits. The corresponding screening tools may be mailed to the study participants 2 weeks before the scheduled well child visits. Those who do not complete the screening tools or those who did not receive them in the mail will then complete the questionnaire in the office prior to seeing their doctor or with their doctor. The PCP will then score the screening tool and interpret the test results. Developmental counseling and/or anticipatory guidance will be provided, as per usual care. EI referral will be completed, at the discretion of the provider with the approval of the caregiver , if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
Study NCT02185599 — intervention group
Intervention type: DEVICE
Intervention: DySIS
Description: Colposcopy performed with the DySIS digital colposcope
Study NCT03711448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone treatment
Description: tapering prednisone regimen
Study NCT01200511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL
Description: Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
Study NCT01791439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: Application of lidocaine to the glossopharyngeal nerve.
Study NCT01791439 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02768129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: active stimulation: 2 milliamp (mA), 20 mins
Study NCT02768129 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcranial direct current stimulation
Description: sham stimulation
Study NCT03352856 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Barley starch
Description: Highly purified barley starch
Study NCT03352856 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maize starch
Description: Maize starch
Study NCT02623361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Nerve Block
Description: Regional Anesthesia by Local Anesthetic Injection
Study NCT02623361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sham Block
Description: Sham Block by saline injection
Study NCT03894540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPN60090
Description: Oral capsules given daily
Study NCT03894540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: An intravenous solution in single-use vial to be diluted for infusion.
Study NCT03711448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone and ustekinumab treatment
Description: Treatment with prednisone and ustekinumab (90 mg subcutaneously at inclusion (W0), W4, W16 and W28)
Study NCT03894540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: An intravenous solution in single-use vial to be diluted for infusion.
Study NCT03894540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPN60090 single administration
Description: Oral capsules given once
Study NCT02441803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3.
Study NCT02441803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 10 mg/m2 by vein on Days -6 to -3.
Study NCT02441803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Salvage Chemotherapy Before Transplant: Clofarabine 15 mg/m2 by vein on Days 6 - 9.~Stem Cell Transplant: Clofarabine 40 mg/m2 by vein on Days -6 to -3.
Study NCT02441803 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: Total body irradiation (TBI) delivered at 2Gy on Day -2.
Study NCT02441803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Thymoglobulin 2.0 mg/Kg by vein on Days -3 and -2.
Study NCT02441803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Fresh or cryopreserved bone marrow or peripheral blood (PB) progenitor cells infused on Day 0. Goal is to infuse 4 X 106 CD34+ cells/kg if PB or >3.0 X 108 marrow mononuclear cells/kg if bone marrow.
Study NCT02441803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 50 mg/kg by vein on Days +3 and +4.
Study NCT02441803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus 0.015 mg/kg/day by vein or mouth on Day +5.
Study NCT02441803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil 15 mg/kg/dose by vein or by mouth three times a day from Day +5 to Day+100.
Study NCT02441803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20 mg/m2 by vein on Days 1 - 5.
Study NCT02441803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 1 g/m2 by vein on Days 6 - 10.
Study NCT02441803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: 10 mg/m2 by vein on Days 6 - 8.
Study NCT04381000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Group
Description: The group follows warm up exercise (maximum 10 minutes). This consisted of combined, breathing techniques, low-impact aerobic exercises, free range of motion exercises of upper and lower limbs and spine, and coordination-based exercises of hands and feet. Breathing techniques take regular activities such as sitting, walking, and lying down. At the end of this phase, active stretching exercises of major muscles of arm, leg and trunk were performed.
Study NCT04711421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4 VIVOFIT-
Description: Feedback on number of steps taken by patint, as recorded by pedometers, provided by research team
Study NCT03450850 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NOVOTTF-200A
Description: NOVOTTF-200A will be administered under appropriate guidelines. Monthly adherence rate >= 75% (>= 18 hours/day) over a 4-week cycle (28 days) will be strongly encouraged.
Study NCT03455543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Provant Therapy System
Description: Treatment with active Provant Therapy System
Study NCT03455543 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive (sham) Provant Therapy System
Description: Treatment with inactive Provant Therapy System
Study NCT02685150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Tri-Modal Imaging
Description: Endoscope that combines white light imaging (WLI) with autofluorescence imaging (AFI) and narrow band imaging (NBI).
Study NCT02685150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole is one kind of proton-pump inhibitors. All participants undergo standard proton-pump inhibitor (PPI) tests for two weeks with Omeprazole, 20mg twice a day.
Study NCT02685150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analysis of gastric juice
Description: Analysis of gastric juice including routine, biochemical and microbiological analysis.
Study NCT02844738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: [StroMed + platelet rich plasma (PRP)]
Description: Patients will be treated with autologous StroMed obtained by the Adipose Ultrasonic Cell Recovery Unit and Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints at the time of initial treatment. Thereafter the affected joints will be treated as direct injections to the joint with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product. Day 0 \[StroMed + platelet rich plasma (PRP)\], Days 7 and 14 \[PRP\]
Study NCT02287246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-Release liposomal bupivacaine (Exparel)
Description: 20mL
Study NCT02287246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 20mL
Study NCT03682575 — intervention group
Intervention type: OTHER
Intervention: Enrollment
Description: All infants whose families consent will be enrolled and will all receive the same treatment which included measurements of work of breathing.
Study NCT03711448 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaires
Description: HAQ ; SF-36 ; FACIT-fatigue
Study NCT03711448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: HAQ ; SF-36 ; FACIT-fatigue
Study NCT03711448 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples
Description: Additional blood samples for immunomonitoring
Study NCT03711448 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Additional blood samples for immunomonitoring